→ THE CATALYST
Immuron signs exclusive U.S. distribution deal with Calmino for PROIBS digestive-health device, igniting micro-float squeeze
- Pre-market PR: exclusive U.S. PROIBS distribution pact with Sweden's Calmino group AB
- Company targeting slice of $4.16B U.S. gut-health market
- 8.1M float, $9M cap; 52.8M shares traded = ~6.5x float rotation
- Watch $2.13 intraday high; prior close ~$1.17 area is key support
▲ RISK FLAGS · LOW FLOAT · MICRO-CAP · DISTRIBUTION DEAL (NOT FDA/EARNINGS) · DILUTION RISK · PRIOR DELISTING FLAG ON MARKETBEAT
AI PRICE TARGETS · 30 DAY
TARGET 1$2.35 +27.7%
A break of the $2.13 intraday high on a 6.5x float rotation typically triggers a squeeze continuation into the next round number, with the $4.16B TAM narrative giving momentum traders a clean bull thesis to lean on.
TARGET 2$3.20 +73.9%
With only 8.1M float and a $9M cap, a sustained bid from the Calmino distribution pact plus a follow-on PR or social media pickup could produce a second leg squeeze similar to prior sub-$10M cap runners that doubled within a month.
STOP — THESIS INVALIDATED$1.17 -36.4%
Loss of the prior close at $1.17 signals the entire gap has been faded and momentum longs are trapped, invalidating the breakout and opening a fill back toward pre-catalyst levels.
AI‑GENERATED · NOT ANALYST TARGETS · NOT FINANCIAL ADVICE
$1.73 · +55.0% · VOL 67.2M · MCAP $9M